We are live on
!
Find out more
ACM
Altium Capital Management Portfolio holdings
AUM
$42M
This Fund
S&P 500
This Quarter
Est. Return
+4.3%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$192M
AUM Growth
+$59.6M
(+45%)
Cap. Flow
+$64.9M
Cap. Flow
% of AUM
33.84%
Top 10 Holdings %
Top 10 Hldgs %
51.67%
Holding
90
New
22
Increased
13
Reduced
5
Closed
18
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ALIM
Alimera Sciences
ALIM
|
+$9.7M |
| 2 |
Amylyx Pharmaceuticals
AMLX
|
+$7.39M |
| 3 |
Sagimet Biosciences
SGMT
|
+$6.43M |
| 4 |
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
|
+$6.39M |
| 5 |
Biohaven
BHVN
|
+$5.97M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
|
+$11.7M |
| 2 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
+$4.23M |
| 3 |
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
|
+$3.57M |
| 4 |
GRI
GRI Bio
GRI
|
+$1.7M |
| 5 |
Harmony Biosciences
HRMY
|
+$1.14M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 88.02% |
| 2 | Consumer Staples | 0.32% |
| 3 | Communication Services | 0.27% |
| 4 | Materials | 0.15% |
| 5 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CBAY
1
DELISTED
Cymabay Therapeutics
CBAY
| $11.9M | 6.22% |
800,000
+131,298
| +20% | +$1.74M |
|
2
PUT
Immunovant
IMVT
$7.9B
| $11.5M | 6.01% |
+300,000
| New | +$6.78M |
|
|
IMGN
3
DELISTED
Immunogen Inc
IMGN
| $11.5M | 6% |
725,000
+240,000
| +49% | +$3.99M |
|
|
ATXS
4
DELISTED
Astria Therapeutics
ATXS
| $10M | 5.24% |
1,347,088
| – | – |
|
5
Xtant Medical Holdings
XTNT
$59.1M
| $9.83M | 5.13% |
8,934,362
+2,706,803
| +43% | +$2.9M |
|
|
6
Amylyx Pharmaceuticals
AMLX
$2.15B
| $9.79M | 5.11% |
534,700
+349,700
| +189% | +$7.39M |
|
7
ADMA Biologics
ADMA
$2.01B
| $9.75M | 5.08% |
2,723,011
+343,011
| +14% | +$1.32M |
|
|
ALIM
8
DELISTED
Alimera Sciences
ALIM
| $9.1M | 4.74% |
+2,934,108
| New | +$9.7M |
|
9
Structure Therapeutics
GPCR
$3.39B
| $7.82M | 4.08% |
+155,000
| New | +$5M |
|
10
Crinetics Pharmaceuticals
CRNX
$8.88B
| $7.79M | 4.06% |
262,000
+127,000
| +94% | +$2.62M |
|
11
Xenon Pharmaceuticals
XENE
$6.23B
| $7.79M | 4.06% |
228,000
| – | – |
|
|
12
Biohaven
BHVN
$2.05B
| $7.46M | 3.89% |
+287,000
| New | +$5.97M |
|
13
Axsome Therapeutics
AXSM
$11.8B
| $6.43M | 3.35% |
92,000
+52,000
| +130% | +$3.89M |
|
|
KRTX
14
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $5.75M | 3% |
+34,000
| New | +$6.39M |
|
15
MoonLake Immunotherapeutics
MLTX
$1.57B
| $5.02M | 2.62% |
88,000
| – | – |
|
16
Vera Therapeutics
VERA
$2.32B
| $4.57M | 2.39% |
333,681
+213,681
| +178% | +$3.67M |
|
|
17
Sagimet Biosciences
SGMT
$440M
| $4.25M | 2.22% |
+483,181
| New | +$6.43M |
|
18
Olema Pharmaceuticals
OLMA
$989M
| $4.14M | 2.16% |
335,000
+25,000
| +8% | +$255K |
|
|
19
Harmony Biosciences
HRMY
$2.07B
| $3.83M | 2% |
117,000
-32,889
| -22% | -$1.14M |
|
|
APLS
20
PUT
DELISTED
Apellis Pharmaceuticals
APLS
| $3.8M | 1.98% |
+100,000
| New | +$4.39M |
|
21
Sarepta Therapeutics
SRPT
$1.62B
| $3.55M | 1.85% |
29,300
+1,300
| +5% | +$147K |
|
22
Dyne Therapeutics
DYN
$4.23B
| $2.82M | 1.47% |
315,000
+160,000
| +103% | +$1.72M |
|
23
Aclaris Therapeutics
ACRS
$723M
| $2.76M | 1.44% |
+403,000
| New | +$3.44M |
|
24
Acumen Pharmaceuticals
ABOS
$160M
| $2.7M | 1.41% |
+650,000
| New | +$4.02M |
|
25
Replimune Group
REPL
$428M
| $2.65M | 1.38% |
155,000
+25,000
| +19% | +$491K |
|
Similar funds
TA
SIM
LSA
VEPM
GC
VI
BCM
VAM
Altium Capital Management's Q3 2023 Portfolio in Review
As of Q3 2023, Altium Capital Management held 90 positions worth $192M, up 45% from $132M the previous quarter. Its ten largest holdings account for 52% of the portfolio.
Altium Capital Management deployed $64.9M of net new capital in Q3 2023, opening 22 new positions and adding to 13 existing holdings. Its largest new stake was Alimera Sciences: 2,934,108 shares worth $9.1M.
By sector, the portfolio is most concentrated in Healthcare at 88% of assets, down from 92% a quarter earlier, followed by Consumer Staples and Communication Services.
On the sell side, the largest reduction was GRI Bio, an estimated $1.7M trimmed.
- Altium Capital Management's largest Q3 2023 buy was Alimera Sciences: 2,934,108 shares worth $9.1M.
- Altium Capital Management added most to Amylyx Pharmaceuticals in Q3 2023, an estimated $7.39M increase.
- Altium Capital Management's biggest Q3 2023 reduction was GRI Bio, cutting an estimated $1.7M.
- Altium Capital Management fully exited Chinook Therapeutics, Inc. Common Stock in Q3 2023, selling an estimated $11.7M.
- Altium Capital Management's ten largest holdings make up 52% of its $192M portfolio in Q3 2023.
- Altium Capital Management opened 22 new positions and closed 18 in Q3 2023.
- Altium Capital Management's portfolio value rose 45% quarter-over-quarter to $192M.
Based on Altium Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.